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ABSTRACT
Challenges and special aspects related to the management and prognosis of pulmonary hypertension (PH) in middle- to
low-income regions (MLIRs) range from late presentation to comorbidities, lack of resources and expertise, cost, and rare
options of lung transplantation. Expert consensus recommendations addressing the specific challenges for prevention
and therapy of PH in MLIRs with limited resources have been lacking. To date, 6 MLIR-PH registries containing mostly
adult patients with PH exist. Importantly, the global prevalence of PH is much higher in MLIRs compared with high-
income regions: group 2 PH (left heart disease), pulmonary arterial hypertension associated with unrepaired congenital
heart disease, human immunodeficiency virus, or schistosomiasis are highly prevalent. This consensus statement provides
selective, tailored modifications to the current PH guidelines to address the specific challenges faced in MLIRs, resulting
in the first pragmatic and cost-effective consensus recommendations for PH care providers, patients, and their families.
(J Am Coll Cardiol 2020;75:2463–77) © 2020 The Authors. Published by Elsevier on behalf of the American College of
Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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P ulmonary hypertension (PH) is a com-plex condition that associates withmultiple diseases and may affect
several organs beyond the cardiovascular
and respiratory systems. Challenges intrinsic
to clinical programs in middle- and low-
income regions (MLIRs) affect diagnosis and
treatment of PH. These challenges range
from lack of resources to cost of care, limited
expertise, unpredictable availability of med-
ications, and the extremely rare option of
lung transplant (1–4). The disease spectrum
is further complicated by late presentation
and coexisting comorbidities (i.e., infections,
malnutrition, and hypercoagulability). Addi-
tionally, lack of data from MLIRs leads to
extrapolation of etiology, diagnosis, and
management algorithms from high-income
regions (HIRs) that may not address some of
the contextual issues intrinsic to MLIRs (2,3).
The purpose of this expert consensus
statement is to highlight the specific chal-
lenges in the diagnosis and treatment of PH in MLIRs.
Following a pragmatic approach with clear cost-risk-
benefit consideration, we developed a consensus
statement with a focus on PH in children and young
adults. This consensus statement does not replace
but must be seen as supplementary to previously
published recommendations and guidelines by the
European Society of Cardiology (ESC) and European
Respiratory Society (5), the American Heart Associa-
tion/American Thoracic Society (6), the publications
produced by the World Symposium on Pulmonary
Hypertension (WSPH) 2018 (7–9) and the European
Pediatric Pulmonary Vascular Disease Network
(EPPVDN) (10). We will not discuss all aspects of PH
covered in the aforementioned papers. Health care
practitioners from MLIRs are encouraged to read the
ESC/European Respiratory Society guidelines (5),
along with the update on pediatric PH provided by
the WSPH and the 2019 updated guidelines of the
EPPVDN (10), and then use this document to help
modify practices contextualized to their own setting.
The current PH registries in MLIRs have minimal
information on patients <18 years of age; thus, the
suggested recommendations on the care of children
with PH in this document are an extrapolation from
both adults with PH in MLIRs and children with PH in
HIRs (10); they are primarily based on expert opinion.
Several etiologies in children and young adults living in
MLIRs are discussed. The importance of such a document
still exists given the challenges associated with such a
disease in a limited resource environment as MLIRs.
METHODS
GOALS AND COMPOSITION OF THE EPPVDN WRITING
GROUP (PH IN MLIRs). The EPPVDN is a registered
nonprofit organization that strives to define and
develop effective, innovative diagnostic methods and
treatment options in all forms of PH (Supplemental
Methods). Most recently the EPPVDN has revised
their 2016 executive summary (11) to develop 2019
updated guidelines on pediatric PH (10) acknowl-
edging the changes put forward at WSPH 2018 (7–9).
Here, we highlight and discuss the challenges and
special aspects in the diagnosis and treatment of PH in
MLIRs, and for the first time, give specific expert
recommendations. This expert consensus statement
is not restricted to pediatric patients and includes
disease etiologies and the management of PH in both
children and (younger) adults in MLIRs. We defined
MLIR as a region where the majority of people live in
countries that have a gross national income (previ-
ously known as gross national product), below 10,000
U.S. dollars per capita, as published by The World
Bank. The executive writing group members for this
consensus statement on PH in MLIRs were recruited
fromAustria, Belgium, Bolivia, China, Germany, India,
Mozambique, Pakistan, South Africa, and Ukraine.
HIGHLIGHTS
 PH in MLIRs is under-recognized; PAH
due to CHD/HIV/schistosomiasis and
group 2 PH (left heart disease) are more
prevalent in MLIRs than in HIRs.
 Unmet need for specific, feasible recom-
mendations for the diagnosis and treat-
ment of PH in MLIRs.
 Here, an expert consensus panel pro-
poses such recommendations for the
global management of PH in MLIRs.
 PH registries and intensified collabora-
tions between MLIRs are required.
ABBR EV I A T I ON S
AND ACRONYMS
AVT = acute pulmonary
vasoreactivity testing
CHD = congenital heart disease
COR = class of
recommendation
echo = echocardiography
EPPVDN = European Pediatric
PVD Network
HFpEF = heart failure with
preserved ejection fraction
HIR = high-income region
LHD = left heart disease
LOE = level of evidence
MLIR = middle- to low-income
region
PVD = pulmonary vascular
disease
SCD = sickle cell disease
WSPH = World Symposium on
Pulmonary Hypertension
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stitutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit
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Manuscript received February 26, 2020; revised manuscript received March 19, 2020, accepted March 23, 2020.
Hasan et al. J A C C V O L . 7 5 , N O . 1 9 , 2 0 2 0
Pulmonary Hypertension in Middle- and Low-Income Regions M A Y 1 9 , 2 0 2 0 : 2 4 6 3 – 7 7
2464
LITERATURE SEARCH, GRADING SYSTEM OF
RECOMMENDATIONS, AND REVIEW PROCESS.
L i terature search . We conducted computerized
searches of the PubMed/MEDLINE bibliographic
database from January 1990 to January 2020. Clinical
trials, consensus statements, guidelines, meta-
analyses, and comprehensive clinical reviews were
searched using the terms “pulmonary hypertension”
and up to 10 other key words. The writing group
members discussed the topics during several face-
to-face and web-based meetings (2018 to 2019).
Class of recommendat ion , Level of Ev idence .
Details on the ESC/American Heart Association
grading system for Class of Recommendation (Table 1)
and Level of Evidence (Table 2), as well as the voting,
peer review, and endorsement process can be found
in the Supplemental Appendix. Importantly, health
care providers must adhere to the medication labeling
and follow future drug recommendations/warnings,
published by regulatory agencies, such as the Euro-
pean Medicines Agency and the U.S. Food and Drug
Administration, when transferring these recommen-
dations into clinical practice. Challenges specific to
MLIRs will be discussed in each section of this paper
and consensus recommendations will be presented at
the end of the document.
DEFINITION OF PH AND PAH IN MLIRs. PH is
currently defined as a mean pulmonary artery pres-
sure (mPAP) >20 mm Hg at rest in patients
>3 months, at sea level, determined by cardiac cath-
eterization (8,12). Because invasive pressure mea-
surements are infrequently used for diagnosis of PH
in MLIRs, transthoracic echocardiography (echo) is
the mainstay of diagnostic screening in such regions.
The right ventricular (RV) to right atrial (RA) pressure
gradient was estimated by continuous wave Doppler
echo (via tricuspid regurgitation velocity [TRV]), and
an estimated RV-RA systolic gradient >50 mm Hg
(TRV >3.5 m/s) was used as a noninvasive cut-off to
define PH (2,3). Of note, such a noninvasive definition
may lead to an underestimation of patients with PH in
these registries. The etiologies of PH are diverse and
differ based on patients’ age and geographic location.
Such information may be important, especially when
deciding on resource allocation and cost of care for
diagnosing and managing patients with PH in MLIRs
(3,5). Details on hemodynamic definitions of PH sub-
types can be found in the Supplemental Appendix.
EPIDEMIOLOGY (DISEASE BURDEN) AND
ETIOLOGY OF PH IN MLIRs
Data is sparse to determine the global prevalence and
incidence of PH. The estimated global prevalence of
PAH is between 15 and 60 per 1 million adults (13).
There is a dearth of data on the incidence, prevalence,
and causes of PH (pre-capillary, post-capillary, and
combined forms) in MLIRs. Although there are regis-
tries in some of the MLIRs (Central Illustration), most
of them only have data on patients with group 1 PH
(e.g., PAH), include mostly patients >18 years of age,
and have limited patient numbers (Table 3). Although
the PAPUCO (Pan African Pulmonary Hypertension
Cohort) (Africa) (3), PRO-KERALA (Pulmonary Hy-
pertension Registry of Kerala, India) (India) (2), and
Ukrainian (14) registries included most groups of PH
patients (groups 1 to 5 PH), these data cannot be
considered to be representative for all different cau-
ses of PH in other MLIRs. The overall burden of PH in
MLIRs is several times higher than that of HIRs, as
demonstrated in the Kerala registry where the esti-
mated incidence was probably 48 per 1 million people in
2015 (2). The following conditions are likely to contribute
substantially to the disease burden of PH in MLIRs:
 Rheumatic heart disease, which is still a scourge in
most MLIRs.
 Untreated congenital heart disease (CHD): only a
small fraction (<10%) of infants with shunt lesions
from CHD receive timely intervention in MLIRs
(surgery or percutaneous device closure).
 PH due to left heart disease (LHD) (group 2 PH) as a
result of a high burden of coronary artery disease
TABLE 1 Classes of Recommendations
COR Definition Suggested Wording to Use
COR I Evidence and/or general agreement that a
given treatment or procedure is
beneficial, useful, and effective.
Is recommended/is indicated
COR II Conflicting evidence and/or a divergence of
opinion about the usefulness/efficacy
of the given treatment or procedure.
COR IIa Weight of evidence/opinion is in favor of
usefulness/efficacy.
Should be considered
COR IIb Usefulness/efficacy is less well established
by evidence/opinion.
May be considered
COR III Evidence or general agreement that the
given treatment or procedure is not
useful/effective and in some cases may
be harmful.
Is not recommended
Classes of recommendations (COR), as currently proposed by the European Society of Cardiology and the
American Heart Association. This color coding for COR can be found in Table 7.
TABLE 2 Levels of Evidence
LOE A Data derived from multiple randomized clinical trials or meta-analyses.
LOE B Data derived from a single randomized clinical trial or large non-randomized studies.
LOE C Consensus of opinion of the experts and/or small studies, retrospective studies,
registries.
Levels of evidence (LOE), as currently proposed by the European Society of Cardiology and the American Heart
Association. This color coding for LOE can be found in Table 7.
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and unrecognized and untreated systemic arterial
hypertension (15,16).
 PH due to lung disease: especially interstitial or
parenchymal lung disease pertaining to high
prevalence of tuberculosis (23% of patients in
PAPUCO) in MLIRs (3). Parenchymal lung disease
caused by smoking, exposure to air pollutants, and
smoke generated during indoor cooking/heating
without chimney (32% in PAPUCO) (3).
 Schistosomiasis is endemic in several parts of the
world especially in South America, the Caribbean,
Sub-Saharan Africa, and South Asia. It is estimated
that 5 to 20 million people worldwide experience
the clinical manifestation of PAH caused by Schis-
tosoma parasite infection (17).
 Human immunodeficiency virus (HIV) infection in
endemic regions (35% of patients in PAPUCO) (3).
 The burden of idiopathic pulmonary arterial hyper-
tension (IPAH) and other conditions listed in the
WSPH PH classification is also substantial, simply
because of the large populations in MLIR regions.
Differences in etiologies between HIRs and MLIRs
are evident from the finding that IPAH is the largest
subgroup of PH in the European COMPERA
(Comparative, Prospective Registry of Newly Initiated
Therapies for Pulmonary Hypertension) registry (18)
whereas PH-LHD (group 2 PH) was found to be the
most common cause in PH registries from MLIRs.
Among group 1 PH patients (here PAH), unrepaired
CHD accounts for the majority of cases and
CENTRAL ILLUSTRATION 6 Registries on Pulmonary Hypertension in Middle- to Low-Income Regions
Pulmonary Hypertension Registries in Middle- to Low-Income Regions (MLIRs) 
• 2003 patients
• 59% Group 2 PH ;
 21.2% Group 1 PH
• Mortality at 12
 months after
 enrollment in the
 registry: 4.1%
• Rehospitalization at
 1 year: 62%
• 220 patients (5% children)
• Group 1, 2 and 3 PH patients
• NYHA FC: 66% were class III or IV
• Mortality at 6 months after enrollment in the
 registry: 21%
PAPUCO






 1 PH; 18.5%






 at 3 years:
 81.5%Colombian registry
•  159 patients
•  Group 1 PH
•  NYHA FC: 88%
 were class II or III
RECOPILAR (Argentina)
• 170 patients
• Group 1 PH
• NYHA FC: 79% were
 class III or IV
HINPULSAR (Argentina)
• 124 patients
• Group 1 PH
• NYHA FC: 62% were
 class III or IV
Hasan, B. et al. J Am Coll Cardiol. 2020;75(19):2463–77.
PAPUCO (Pan African Pulmonary Hypertension Cohort) involved 4 African countries; PRO-KERALA (Pulmonary Hypertension Registry of Kerala, India) included 50
centers across the state of Kerala in India; HINPULSAR (Hipertensión Pulmonary Asociaciones en la Argentina) included 31 centers in Argentina; RECOPILAR (Registro
Colaborativo de Hipertensión Pulmonaren Argentina); a Colombian registry included 5 centers; and a prospective Ukrainian registry (adult PAH, CTEPH) from a single
referral center in Kyiv, Ukraine. Overall, the majority of the patients in the 6 registries were >18 years of age. CTEPH ¼ chronic thromboembolic pulmonary
hypertension; NYHA ¼ New York Heart Association functional class; PAH ¼ pulmonary arterial hypertension; PH ¼ pulmonary hypertension.
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contributes substantially to the overall disease
burden of PH in MLIRs. Table 4 summarizes the fea-
tures of different PH groups and some of the specific
recommendations relevant to MLIRs.
CLINICAL PRESENTATION AND
DIAGNOSIS OF PATIENTS WITH PH IN MLIRs
Untreated, undiagnosed PH patients in MLIRs present
late at definitive diagnosis and with more advanced
functional deterioration compared with HIRs
(Table 3). Similar functional impairment at presenta-
tion was observed in the Latin American registries too
(Table 3) (19). Such late presentation with advanced
disease is a major contributor to the very high mor-
tality in PH patients living in MLIRs (Table 3) (2,3).
Indeed, patients with CHD and significant left-to-
right shunts frequently present late in MLIRs and
often have severely increased pulmonary vascular
resistance (PVR). Some of these PAH-CHD patients
may still be operable, despite their older age at pre-
sentation, thus warranting comprehensive and care-
ful invasive assessment to determine operability
(20,21). Our recommendations for the overall
approach to determine operability of a cardiovascular
shunt lesion in MLIRs is summarized in Supplemental
Table 1.
DIAGNOSTIC WORK-UP. Identifying PH. Transthoracic
echo is the main diagnostic modality for diagnosis of
PH, as many patients in MLIRs do not undergo a
diagnostic “gold standard” cardiac catheterization
(2,3). Using TRV, based on the continuous wave
Doppler envelope, as a measure of RV systolic pres-
sure in PH may still result in underdiagnosing the
disease. A detailed, multiparameter assessment of the
right heart using a standardized protocol (10,22) will
likely increase the accuracy of echo in detecting PH.
Once PH is judged to be highly likely, a diagnostic
approach should be adopted that helps identify cau-
ses with a high likelihood of occurrence and preva-
lence in a given region/country (Table 4).
Diagnost i c work-up for suspected PH in
MLIRs . A systematic approach to patients with PH in
MLIRs may help identify causes in a cost-effective
manner (Figure 1, Supplemental Table 2).
Detailed history and physical examination: Helps to
identify a cause and evaluates the clinical status of
the patient. A detailed family history is imperative to
diagnose familial or hereditary PAH.
Chest x-ray: Identifies potential pulmonary etiol-
ogy or indirect contributors, such as spinal deformity.
Signs of left-sided heart disease may suggest group 2
PH (23).
Transcutaneous pulse oximetry and arterial blood gas
analysis: Can provide information regarding paren-
chymal/interstitial lung disease (diffusion impair-
ment) and also operability in CHD shunt lesions (24).
Pulse oximetry screening in both the right upper and
TABLE 3 Characteristics of Pulmonary Hypertension Registries in Middle- to Low-Income Regions (MLIRs)
Registry/Reference Region Demographic Data Main Findings
PAPUCO Registry Africa 209 adults (median age 48 yrs; IQR: 35.6) and
11 children (age 1–17 yrs) included, 9 specialist
centers in 4 African countries (Nigeria, Cameron,
South Africa, and Mozambique).
69% had left heart disease (Group 2 PH) and 16% had PAH
(Group 1 PH), 11% PH due to lung disease (Group 3 PH);
66% had NYHA functional class III–IV status, 21% mortality
over 6-month follow-up.
Pro-KERALA Registry Kerala, Southern
India
2,003 adults (mean age 56  16.1 yrs) enrolled over
1 yr from 50 hospitals; estimated incidence is
48 per million adult population.
Mortality (1 yr): 4.1%.
Rehospitalization (1 yr): 62%.
Majority (59%) had left heart disease (Group 2 PH); w20% were
PAH (Group 1 PH); w5% had IPAH (Group 1 PH); w50% of PAH
patients received oral PAH-targeted therapies.
HINPULSAR* Argentina 124 adult patients (mean age 45  17 yrs) from
31 centers recruited prospectively over 1 yr.
PAH patients only (Group 1 PH): 52% IPAH and 27% CHD-PAH,
78% females. 62% presented in NYHA functional class III/IV.
RECOPILAR† Argentina 170 adult patients (mean age 51 yrs) recruited
prospectively over 1 yr. Only PAH patients
(Group 1 PH) enrolled.
PAH patients only (Group 1 PH). 52% IPAH, 27% CHD-PAH;
79% women. 70% presented in NYHA functional class III/IV.
Colombian Registry‡ Bogota, Colombia 159 patients (age >18 yrs) recruited retrospectively
over 6 yrs from 5 centers. Only PAH (Group 1
PH) and CTPEH (Group 4 PH) patients enrolled.
PAH (Group 1 PH) and CTPEH (Group 4 PH) patients only. 33% had
CTEPH, 58% men. 88% presented in NYHA functional class II
and III.
Ukrainian Registry (14) Kyiv, Ukraine 281 patients (mean age 41.7  14.6 yrs) recruited
prospectively between June 2014 and July 2018
from 1 center. 52 patients with CTEPH
(Group 4 PH) and 229 with PAH (Group 1 PH).
Follow-up period was up to 51 months. The Kaplan-Meier survival
rate for the total cohort was 93.3%, 86.8%, and 81.5% at 1, 2,
and 3 yrs.
Data from: *Perna ER, Coronel ML, Echazarreta D et al. Epidemiological profile of pulmonary arterial hypertension in Argentina: insights from HINPULSAR registry. Eur J Heart Fail 2012:Suppl 1:S55. †Lescano
A, Talavera L, Mazzei J, et al. on behalf of RECOPILAR. The advanced functional class and the variables of poor prognosis in pulmonary hypertension. Eur J Heart Fail 2016;18 (suppl. 1):122. ‡Villaquiran C,
Conde R, Torres A, Duenas R. Description of the clinical, functional and hemodynamic characteristics of patients with CTEPH in five reference centers in Bogota-Colombia, at 2.640 meters above sea level. Am
J Respir Crit Care Med 2015;191:A4846.
CHD ¼ congenital heart disease; CTEPH ¼ chronic thromboembolic pulmonary hypertension; IPAH ¼ idiopathic pulmonary arterial hypertension; IQR ¼ interquartile range; MLIR ¼ middle- to low-income
region; NYHA ¼ New York Heart Association; PAH ¼ pulmonary arterial hypertension; PH ¼ pulmonary hypertension.
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any lower extremity is recommended for evaluating
post semilunar valve shunt lesions (i.e., patent ductus
arteriosus or aorto-pulmonary window).
Lung function tests: May help to identify airway
pathologies such as unrecognized asthma or intersti-
tial lung disease.
Specific laboratory tests: Work-up to evaluate for
autoimmune disorders, when clinically appropriate
(23), should be performed. Screening for and diag-
nosis of HIV in endemic areas is essential.
Abdominal ultrasound: Can help identify diseases
leading to porto-PH or other rare diagnoses such as
the Abernethy malformation (25).
Computed tomography chest and lung perfusion
scans: Might help identify chronic thromboembolic
pulmonary hypertension (CTEPH). CTEPH is poten-
tially treatable and can be identified through either of
these tests. Chest computed tomography, if available,
is important to rule out parenchymal/interstitial lung
disease in suspected PH.
Cardiac catheterization and acute pulmonary vas-
oreactivity testing (AVT): A number of institutions in
MLIRs now have cardiac catheterization laboratory
facilities. Although inhaled nitric oxide is largely
unavailable, preliminary data suggests that inhaled
iloprost (5 mg through a nebulizer over 15 min) and
intravenous sildenafil can be used effectively for
AVT at a fraction of the cost compared with inhaled
nitric oxide (iNO) (26). Oxygen alone is insufficient
and not useful to test for AVT (5). However, oxygen
alone may be useful when lung disease and diffu-
sion impairment is suspected to be the major cause of
PH and to determine oxygen-dependence of PAP
elevation.
ASSESSMENT OF FUNCTIONAL STATUS AND PH RISK
STRATIFICATION. After PH diagnosis is made
TABLE 4 The 5 PH Groups and Specific Considerations in Middle- to Low-Income Regions (MLIRs)
PH Classification Global Prevalence* Features to be Considered in MLIRs Recommendations to be Considered in MLIRs





1.3 Drug- and toxin-induced PAH
Prevalence 15-60 per million True incidence and prevalence of HPAH
may be higher in regions with high
rates of consanguinity
Genetic testing may not be feasible due to cost or
lack of availability; detailed family history is
imperative
1.4 PAH associated with:
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis
Some report prevalence of 0.5
per 1,000 adults with HIV-
related PAH in Africa
(probably overestimated)
Higher incidence and prevalence of late
presenting and unrepaired CHD, HIV,
HBV/HCV-induced cirrhosis and portal
hypertension
Screening for unrecognized or latent infections (HIV,
HBV/HCV, schistosomiasis) may be included in
the initial workup
1.5 PAH long-term responders to calcium-
channel blockers
1.6 PAH with overt features of venous/
capillaries (PVOD/PCH) involvement
Underrated due to unrecognized HIV,
history of excessive radiation
exposure, consanguinity
1.7 Persistent PH of the newborn
syndrome
High incidence of prematurity, IUGR
and intrauterine infections may lead
to significant burden of PPHN or CLD
Education of neonatologists to recognize PPHN-
and CLD-related pulmonary hypertension; proper
follow-up of neonates with PPHN
Group 2: PH due to left heart disease
2.1 PH due to heart failure with preserved
LVEF
2.2 PH due to heart failure with reduced
LVEF
2.3 Valvular heart disease
2.4 Congenital/acquired cardiovascular
conditions leading to post-capillary PH
3-4 million people with
rheumatic heart disease
(RHD)-related PH worldwide
High incidence and prevalence of
advanced RHD valvular disease
Reduction in RHD burden is an enormous challenge
that needs a concerted global effort. The World
Heart Federation roadmap serves as a foundation
for the development of tailored plans of action to
improve RHD control in specific contexts.
Group 3: PH due to lung diseases and/or
hypoxia
High incidence and prevalence of
TB-related lung disease
Group 4: PH due to pulmonary artery
obstructions
4.1 Chronic thromboembolic PH
4.2 Other pulmonary artery obstructions
Group 5: PH with unclear and/or
multifactorial mechanisms
5.1 Hematological disorders
5.2 Systemic and metabolic disorders
5.3 Others
5.4 Complex congenital heart disease
1-2.5 million people affected by
sickle cell-related PH
worldwide
High incidence and prevalence of sickle
cell disease, thalassemia, chronic
renal failure
Centers are needed with expertise in treating benign
hemoglobinopathies and its related
complications
*Per million adults or individuals affected worldwide. PH classification according to the World Symposium on PH 2018, see Simonneau G, et al. (8).
CHD ¼ congenital heart disease; CLD ¼ chronic lung disease; HCV ¼ hepatitis C virus; HBV ¼ hepatitis B virus; MLIR ¼ middle- and low-income regions; IUGR ¼ intrauterine growth restriction;
TB ¼ tuberculosis.
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(noninvasively or preferably invasively), functional
status (exercise capacity) and PH risk stratification of
the patient can be determined using history (World
Health Organization functional class), easily per-
formed tests like the 6-min walk test (in patients age
>6 years), echo assessment of RV function and
catheter-based hemodynamic data (10)
(Supplemental Table 3). The EPPVDN developed a
new risk score for children with PH (10) that needs to
be validated in future prospective studies.
MANAGEMENT OF PH IN THE CONTEXT OF
FINANCIAL AND INFRASTRUCTURAL
CONSTRAINTS IN MLIRs
Due to several factors intrinsic to MLIRs, ranging from
access to health care to unavailability of treatment
and cost (2,3,27–29), both managing PH patients
and improving their ultimate outcome in MLIRs are
major challenges (27–29) (Table 6, Supplemental
Table 4). It is imperative that practitioners in
MLIRs modify the management recommendations
that apply in HIRs to keep the overall essence but
to make it practical according to the constraints in
the MLIR setting. Without such a pragmatic
approach, maintaining patient compliance will be
difficult and management will be ineffective in the
end.
PAH-TARGETED PHARMACOTHERAPY. Targeted phar-
macotherapy is approved for PAH (group 1 PH); some
PAH-targeted medications are also approved for use
in CTEPH (group 4 PH) (Supplemental Table 4). Using
PAH-targeted medications in other groups of PH
(e.g., combined pre- and post-capillary PH) should be
TABLE 5 PAH-Specific Medications and Special Considerations in Middle- to Low-Income Regions (MLIRs)*
Medication Class Mode of Delivery Special Considerations in MLIRs
CCBs (e.g., amlodipine) Oral  Lack of ability to perform AVT makes it difficult to diagnose acute responders
vs. nonresponders; thus, use of CCB may not be feasible.
 CCBs are contraindicated in PAH-CHD with large shunt and in Eisenmenger
Syndrome.
 CCBs are contraindicated in patients who have not undergone AVT, in proven
non-responders to AVT, and in those with poor cardiac function and/or right
heart failure, regardless of AVT response.
 Ability to follow-up to ensure “responder” status may not be possible.
Phosphodiesterase-5 inhibitors (e.g.,
sildenafil, tadalafil)
Oral i.v. (for special
conditions, i.e., immediate
post-operative)
 Relatively easily available in cheap generic forms (cost w U.S. $2 per 25-mg
oral dose).
 Less side effects; no drug-related adverse event monitoring required.
 Use of medium dose should be encouraged (EMA recommendation 10 mg
3 daily for weight <20 kg and 20 mg 3 daily for weight $20 kg).
Endothelin receptor antagonists (e.g.,
bosentan, ambrisentan, macitentan)
Oral  Making its way to the MLIR markets; still expensive (especially newer agents).
 Monitoring of liver function may be challenging (bosentan).
 Teratogenicity as risk of unplanned pregnancy may be high in MLIRs.




 Limited availability in few MLIR countries such as China.
 Frequency of use may significantly impair compliance for inhaled medication.
 i.v. infusion option is almost nonexistent in MLIRs because of fundamental
health system challenges.
 Expensive.
Soluble guanylate cyclase stimulators (e.g.,
riociguat)
Oral  Limited availability in selected MLIRs.
 Expensive.
Supportive medication: Oral, intravenous
Diuretic agents  Diuretic agents (furosemide, thiazide) should be used with caution given RV
hemodynamics.
Spironolactone  Recommended use of spironolactone, a supportive medication in PAH and
proven to be effective in HFpEF.
Digoxin  Digoxin may be useful particularly in PAH with high heart rates.
Beta-blockers  Avoid chronic use of beta-blockers in adults with PAH (negative RCT have
been published; no pediatric data available).
Iron and vitamins  Treat especially iron deficiency.
Oral anticoagulation  Oral anticoagulant treatment may be considered in adult patients with IPAH,
HPAH, and PAH due to use of anorexigens (COR: IIb, LOE: C).
 Do not pursue oral anticoagulation without a clear indication and proper
follow-up.
 No data exist to recommend oral anticoagulation in children with PH.
 Of note, many patients with severe PAH do have acquired von Willebrand
syndrome and thus an increased bleeding risk per se.
*For specific and detailed dosing recommendations, refer to Hansmann et al. (11).
AVT ¼ acute vasoreactivity testing; CC ¼ cardiac catheterization; CCB ¼ calcium-channel blocker; COR ¼ Class of Recommendation; EMA ¼ European Medical Association; ESC/ERS ¼ European Society of
Cardiology/European Respiratory Society; HFpEF ¼ heart failure with preserved ejection fraction; iNO ¼ inhaled nitric oxide; i.v. ¼ intravenous; LOE ¼ Level of Evidence; RCT ¼ randomized clinical trials;
RV ¼ right ventricle; other abbreviations as in Table 3 and Supplemental Table 4.
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decided upon by PH experts only. Vasodilatory
agents may worsen clinical status and might cause
pulmonary edema, especially in group 2 PH with
heart failure with preserved ejection fraction and left
atrial hypertension of other causes (11). The route of
PAH drug administration, frequency of use, cost, and
availability can be major limiting factors in the
compliance with treatment, especially in MLIRs (2,3).
Several of the PAH drugs are manufactured and
available in some MLIRs, for example, India and
China (Supplemental Table 4). Notwithstanding the
substantially reduced prices, these medications are
still very expensive for the average patient in MILRs.
In India, the monthly cost of therapy with sildenafil
is U.S. $30, whereas dual therapy (tadalafil plus
ambrisentan) is w$100/month (2). Because the ma-
jority of people in India are uninsured and live at or
below $60/month, affording such therapies with
effective treatment compliance is extremely chal-
lenging (2). Such a scenario holds true for other
MLIRs, such as Pakistan, Indonesia, Bangladesh,
Afghanistan, and others. Table 5 describes the clas-
ses, different medications, and specific consider-
ations for PH in MLIRs (see also Table 6,
Supplemental Table 4). The objective of improving
quality of life needs to be discussed up-front with
families to make an informed decision on
costly pharmacotherapy.
TABLE 6 Perspectives for PH Patients in Middle- to Low-Income Regions (MLIRs)
Ukraine, Eastern Europe,
Western Asia/Middle East China and Southeast Asia Indian Subcontinent Africa Middle and South America
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associated PH and










to the adult PAH
population.
High prevalence of RHD and
unrepaired CHD in the South
Asia region. Indoor and
outdoor pollution together
with high prevalence of TB-
related lung injury may
contribute to group 3 PH.
The etiology of PH in Africa is
broad and there is no
systematically collected data
on epidemiology.
Estimates on the prevalence by
underlying disease are:
schistosomiasis (170 million),
RHD (6.5 million), SCD (12
million), HIV (20 million),
moderate to severe COPD (30
million).
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available for free, but
only to selected PAH
patients. No HLTx in
Kazakhstan.
PDE5i, ERA, inhaled and
subcutaneous PCAs
available.
LuTx or HLTx available in
selected centers.
Most pharmacological options
(PDE5i, ERA, inhaled and
subcutaneous prostanoids)
available, but only affordable
to some patients.
Transplantation (LuTx, HLTx)
available in selected centers.
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1 billion Africans.
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High birth rates, overcrowding,
poverty, and disorganized
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to establish register studies
(Pro-KERALA and Pakistan
registry).
Preventive strategies aimed at
reducing smoking, pollution,
elimination of RHD, HIV, and
schistosomiasis might
eventually contribute to











For details, see Appendix.
COPD ¼ chronic obstructive pulmonary disease; ERA ¼ endothelin receptor antagonist; HLTx ¼ heart-and-lung transplantation; LuTx ¼ lung transplantation; PCA ¼ prostacyclin analog;
PDE5i ¼ phosphodiesterase 5 inhibitor; SCD ¼ sickle cell disease; other abbreviations as in Tables 3 and 4.
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Chest X-ray and ECG
Chest X-ray and













The algorithm applies to children and adults living in middle- to low-income regions (MLIRs) with limited health care resources. See Supplemental Table 2.
COPD ¼ chronic obstructive lung disease; CTEPH ¼ chronic thromboembolic pulmonary hypertension; CTPA ¼ chest tomography pulmonary angiography;
ECG ¼ electrocardiogram; echo ¼ echocardiogram; HIV ¼ human immune deficiency virus; HBV ¼ hepatitis B virus; HCV ¼ hepatitis C virus; HRCT ¼ high resolution
computed tomography; LFT ¼ liver function test; LHD ¼ left heart disease; PCP ¼ pneumocystis carinii (newer term: pneumocystis jirovecii); PH ¼ pulmonary
hypertension; SLE ¼ systemic lupus erythematosus; TB ¼ tuberculosis; US ¼ ultrasound; V/Q scan ¼ ventilation to perfusion scan.
J A C C V O L . 7 5 , N O . 1 9 , 2 0 2 0 Hasan et al.
M A Y 1 9 , 2 0 2 0 : 2 4 6 3 – 7 7 Pulmonary Hypertension in Middle- and Low-Income Regions
2471
TABLE 7 Recommendations for Diagnosis and Management of Pulmonary Hypertension in Middle- to Low-Income Regions (MLIRs)
Recommendations COR LOE
Children/young adults with suspected or confirmed PH must be referred to, comprehensively evaluated, and treated in specialized pediatric
centers. In MLIRs, such pediatric centers often have limited resources, and thus children with PH may be referred to centers caring for
adult patients with PH.
I C
The initial evaluation of a child/young adult with PH must include a comprehensive medical history (specifically to identify causes like sickle cell
disease, tuberculosis, or operability in shunt lesions), physical examination (in MLIRs specific causes like rheumatic heart disease) (2,3,23).
I B
Patients in endemic areas of schistosomiasis who present with symptoms and physical signs of PH must undergo a detailed echocardiogram.
Patients from such endemic areas with PH and signs of pre-hepatic portal hypertension may be suspected to have schistosomiasis-related
PH (17,56).
I C
Patients with schistosomiasis infection and PH benefit from PAH- directed therapy (mainly sildenafil) (31). I C
Patient with active schistosomiasis need treatment with an antihelmintic drug, such as praziquantel (32). I C
Patients with rheumatic heart disease (RHD) and PH documented by echocardiography must undergo treatment as per RHD valve treatment
guidelines.
I C
The need for PAH-targeted medications in patients with RHD should be carefully evaluated and eventually pursued only at centers
specializing in PH.
I C
In regions where HIV is highly prevalent, patients with symptoms or signs of PH should undergo a detailed transthoracic echocardiogram to
detect PH (57).
I C
Patients with HIV infection and PH, documented by echocardiography, benefit from PAH specific medication (especially bosentan). The role of
HAART on the prevalence and outcome of PH secondary to HIV is still controversial (49,57,58).
I C
Treatment with PAH-specific medication (especially sildenafil) in patients with SCD-related PH is highly controversial. Oral sildenafil appears
to increase hospitalization rates for pain in SCD, probably related to vaso-occlusive crisis (36).
III harm C
Patients living at high altitude and with symptoms and signs of PH may undergo a detailed transthoracic echocardiogram to detect PH. I C
The initial patient history needs to include all major socioeconomic determinants of compliance (profession, family structure, and proximity
to treating center). Such information is critical to determine the compliance to treatment and subsequent follow-ups in PH patients (3).
I C
Patients with high altitude-related PH probably benefit from PAH specific medications (50). IIa B
Children <2 yrs of age living in MLIRs with PH and so-called “simple shunts” (ASD, VSD, or PDA) who have normal saturations, signs of
increased pulmonary blood flow, and exclusive left-to-right shunt on echocardiography may undergo shunt closure without invasive
hemodynamic evaluation (59,60).
IIb C
In children with cardiovascular shunt lesions, noninvasive oxygen saturations and—if possible—arterial PaO2 during exercise should be measured.
A drop in PaO2 of >10 mm Hg or SpO2 by 19% points during exercise indicates an inoperable shunt due to increased PVR (59–61).
I C
A comprehensive echocardiogram at diagnosis is recommended as this is the main (and may be the only) modality of diagnosing PH. Features
of operability in shunt lesions should also be assessed using echocardiogram. Serial echocardiograms and ECGs may not be feasible in MLIRs
(due to lack of expertise and equipment) or not be cost-effective, and may be performed on a case-by-case basis (2,3,22).
I B
Further imaging (mainly chest CT) is recommended to exclude underlying parenchymal/interstitial lung disease, in ex-premature infants, and in
patients with BPD, Down syndrome, or other well-known risk factors (3,23,59).
I B
Cardiac catheterization for diagnosis or routine follow-up should be performed in PH centers only. Lack of expert centers and standardization
of cardiac catheterization in MLIRs may lead to erroneous data, wrong data interpretation, or little management value. In the absence of
vasoreactivity testing, the value of cardiac catheterization (especially if done for shunt operability) is limited (2,3,62,63).
IIa B
If no underlying cause of the PH is evident, specific tests for HIV, schistosomiasis, and chronic hepatitis (HBV and HCV) must be performed.
An abdominal ultrasound is indicated to rule out liver cirrhosis and/or portal hypertension (2,3,64)
I B
Serial 6MWTs must include pulse oximetry and are recommended to assess exercise tolerance and response to therapy, and to estimate
prognosis in children with PH capable of performing such studies. A 6MWT is an inexpensive, reproducible measure of functional capacity.
Equipment and expertise for CPET are rarely available in MLIRs (65).
I C
PAH-specific therapy is recommended and can significantly improve quality of life. Safety of intravenous therapy in a low-resource setting is
also of concern (higher risk of infection and catheter-based complications). Inhalation therapies are often ineffective due to lack of sufficient
patient compliance and/or difficulties with applying the devices at home (2,3,66).
I B
For children with PH/PHVD undergoing surgery or other interventions requiring sedation or general anesthesia, consultation with cardiac
anesthesia and PH service and appropriate post-procedure monitoring are required (67,68).
I C
Atrial septostomy and other surgical measures (e.g., reverse Potts shunt) and interventional procedures (ductal stenting, balloon atrial
septostomy) may be considered in highly selected cases at very few specialized centers. These procedures are risky per se and especially in
MLIRs, with inconclusive long-term benefits especially in the absence of a lung transplant program (54,55,69).
IIb C
Serial measurements of serum NT-proBNP concentration may be indicated as changes in NT-proBNP reflect hemodynamic impairment.
Cost-benefit assessment of this test is needed in MLIRs health care setting (5).*
IIb C
Recommendations specific to MLIRs are predominantly based on expert opinion due to lack of publications from these regions. *Based on RCT study data not specific to MLIR, serial measurements of serum
NT-proBNP concentration should be considered (COR IIa) as changes in NT-proBNP reflect hemodynamic impairment. These recommendations are taken with permission (slightly modified) from Table 12 in
Hansmann et al. (10).
6MWT ¼ 6-min walk test; ASD ¼ atrial septal defect; CPET ¼ cardiopulmonary exercise testing; HAART ¼ high activity anti-retroviral therapy; NT-proBNP ¼ N-terminal pro-brain natriuretic peptide;
PaO2 ¼ arterial partial pressure of oxygen; PDA ¼ patent ductus arteriosus; PPHVD ¼ pediatric pulmonary hypertensive vascular disease; PVR ¼ pulmonary vascular resistance; PVD ¼ pulmonary vascular
disease; RV ¼ right ventricle; SCD ¼ sickle cell disease; SpO2 ¼ oxygen saturation; VSD ¼ ventricular septal defect; other abbreviations as in Tables 3 and 4.
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PREGNANCY AND CONTRACEPTION. Pregnancy in
female PH patients is associated with substantial risk
of maternal and fetal mortality; thus, relevant coun-
seling is very important, especially in MLIRs (30).
Safer contraception options (i.e., progesterone
impregnated intrauterine coils, subdermal or intra-
muscular progesterone implants/injections) may not
be readily available in MLIRs. Standard oral estrogen-
based contraceptive is associated with increased risk
of thrombosis (30). In the event of pregnancy, if the
mother wants to continue, close follow-up with high-
risk obstetric care is recommended, especially at the
time of delivery and within the 2 weeks postpartum,
when the risk of death is the highest, often due to
thromboembolic complications or heart failure (30).
SPECIAL THERAPEUTIC CONSIDERATIONS
IN MLIRs
PH ASSOCIATED WITH SCHISTOSOMIASIS. Schisto-
somiasis is the most common parasitic disease asso-
ciated with PH (17). The cause of PH in
schistosomiasis is multifactorial, including parasitic
pulmonary artery embolization, pulmonary vascul-
opathy, and portal hypertension related to hep-
atosplenic disease (17) that can be diagnosed by
abdominal ultrasound. A high index of suspicion of
schistosomiasis-induced PH should be present when
patients present with cardiovascular symptoms and
features of PH in schistosomiasis endemic areas
(Supplemental Figure 1) (17). The cornerstone of cur-
rent schistosomiasis control programs is delivery of
praziquantel to at-risk populations. World Health
Organization guidelines recommend annual treat-
ment for schistosomiasis or soil-transmitted helmin-
thiasis when prevalence in school-aged children is at
or above a threshold of 50% and 20%, respectively.
No specific test exists to diagnose schistosomiasis-
induced PH. Patients with schistosomiasis infection
and PH may benefit from PAH-directed therapy
(mainly sildenafil) (31). Patients with active schisto-
somiasis need immediate treatment with an anthel-
mintic drug, such as praziquantel (32).
PH ASSOCIATED WITH SICKLE CELL DISEASE. In a
systematic review of PH in Africa, the prevalence of PH
in sickle cell disease (SCD) was 36.9% (29.7% to 44.3%)
(27) with a mean age of 28.6  5.8 years at presentation
(33). The etiology of PH in SCD is multifactorial, so that
all 5 groups of PH (mainly groups 1 to 3) occur (8,27). PH
in SCD is often linked to left heart failure (27,34,35) due
to chronically elevated cardiac output, LV diastolic
dysfunction, or coronary ischemia. Furthermore, SCD
patients may develop parenchymal lung disease from
recurrent acute chest syndrome, while others develop
CTEPH. Despite PAP being onlymoderately elevated in
most SCD patients, PH has a negative influence on ex-
ercise capacity (33) and markedly increases the risk of
death in SCD patients compared with those without
PH. Treatment with PAH-targeted medication (espe-
cially sildenafil) in patients with SCD-related PH is
controversial and may lead to an increase in SCD-
related vaso-occlusive crisis (36). For most patients
with SCD who have PH (confirmed by cardiac cathe-
terization), we do not recommend administration of
any PAH-targeted therapy (Table 7) (37). Furthermore,
hydroxyurea is the first-line therapy in patients with
SCD who are at increased risk for mortality, according
to American Thoracic Society criteria from 2014
(TRV$2.5 m/s, serum N-terminal pro-brain natriuretic
peptide $160 pg/ml, or presence of PH by cardiac
catheterization, as defined at the time by mean pul-
monary artery pressure $25 mm Hg) (37). Recently,
promising results have been reported using chronic
blood exchange transfusions in SCD with pre-capillary
PH (38).
PH ASSOCIATED WITH THALASSEMIA. The preva-
lence of PH in patients with b-thalassemia intermedia
(TI) is quite high, and exceeds those with b-thalas-
semia major (TM) (4.2% vs. 1.1%) (39). In contrast, PH
is rarely found in patients with a-thalassemia (Bart or
Hemoglobin H disease) (39). Of note, PH in thalas-
semia is multifactorial in nature, that is, chronic he-
molysis leading to impaired NO bioavailability,
restrictive cardiomyopathy due to myocardial side-
rosis, liver siderosis-related cirrhosis or viral hepati-
tis, pulmonary siderosis, transfusion-related HIV
infection, change in circulating erythrocytes post
splenectomy (40), and hypercoagulability leading to
higher risk (1% to 4%) of thromboembolic episodes
(41). Thus, suspected PH associated with any type of
thalassemia requires a careful and systemic approach
to confirm the diagnosis. A high index of suspicion is
required, because symptoms of PH in thalassemia
patients may mimic those related to anemia. Chronic
transfusion protocol with appropriate iron chelation
strategies may prevent and also improve PH in these
patients (42). Hydroxyurea therapy in b-TI and L-
carnitine in TM patients have been shown to improve
PH (43). There is limited data on use of PAH-specific
medication in thalassemia patients. Sildenafil ther-
apy in b-TM patients (44), tadalafil in b-TI patients
(45), and bosentan in b-TI patients have been used.
Due to its liver toxicity, bosentan should be
cautiously used with close monitoring (11). Limited
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data exist on the use of prostacyclin analogs in
these patients.
PH ASSOCIATED WITH HIV INFECTION. HIV-infected
patients have a greater incidence of PH compared with
the general population (46) and a 2,500-fold increased
risk of developing PAH. A systematic review andmeta-
analysis of cardiac dysfunction in HIV reported a
prevalence of PH of 11.5% in 125,382 HIV-infected
adults (5.5% to 19.2%) (47). However, in a prospective
cohort registry of 220 African PH patients, HIV/acute
immune deficiency syndromewas found in<10%of PH
cases (3). HIV-related PAH reduces the probability of
survival by one-half compared with HIV-positive in-
dividuals without PAH (48). Patients with HIV infec-
tion and PH suspected by echo may benefit from PAH-
targeted therapy (especially bosentan) (49). The role of
high-activity antiretroviral therapy on the prevalence
and outcome of PH associated with HIV is still contro-
versial (49).
PH ASSOCIATED WITH HIGH ALTITUDE. PH in the
presence of chronic hypobaric hypoxia is per defini-
tion endemic. In La Paz, Bolivia, at 3,350 m above sea
level (a cohort of 4,469 patients), 206 of 1,217 (17%)
infants <3 months had signs of PH. Based on the La
Paz experience, it is recommended to treat these
newborns and young infants with echo evidence of
PH with PDE5 inhibitors (oral sildenafil 1 mg/kg
bodyweight every 6 h). Older patients, who develop
PH specifically related to high altitude, primarily
need to be referred to lower regions, where pulmo-
nary pressure usually drops to normal levels. No
medication is needed in this clinical scenario in most
instances. Prophylactic use of pulmonary vasodila-
tors to prevent high altitude–induced PH is discour-
aged as in some studies it has been shown to cause
harm (50).
CHD at high altitude occurs with a rather different
anatomical distribution (e.g., patent ductus arterio-
sus [PDA], atrial septal defect, tricuspid atresia, and
Ebstein anomaly are more common than at sea level).
Children living at high altitude have a 10-fold chance
of having a hemodynamically relevant PDA (51). The
presentation and clinical evolution of CHD lesions
also differs at high altitude compared with similar
patients residing at sea level (52). For example, left to
right shunt lesions (PDA, ventricular septal defect)
have a delayed progression toward an inoperable
state and should be assessed for operability even after
childhood.
HYPOXEMIA AND EISENMENGER SYNDROME. Eisen-
menger syndrome is present in unrepaired shunt
lesions and is characterized by cyanosis, clubbing,
and reverse (right–left) flow across the shunt. Goal
of treatment is improving quality of life and dealing
with complications (Supplemental Table 5) that arise
in Eisenmenger syndrome (53). In patients with
Eisenmenger syndrome and neurological symptoms
(minor stroke), phlebotomy may be considered in
severe hyperviscosity (hematocrit $70%); however,
iron deficiency from frequent phlebotomies must be
avoided. Routine phlebotomy is associated with
increased risk of stroke and also leads to relative
anemia and reduction in exercise tolerance.
ATRIAL SEPTOSTOMY OR REVERSE POTTS SHUNT
AS PALLIATIVE OR BRIDGING THERAPIES. Atrial
septostomy or reverse Potts shunt as palliative or
bridging therapies are typically used to improve qual-
ity of life, as a bridge to lung transplantation (54,55), or
as destination therapy (54). Both procedures carry
significant risk and require a high level of expertise.
Very few advanced centers in MLIRs attempt such
interventional therapies (mainly reverse Potts shunt:
surgery or catheter intervention) and consider them
only in selected cases. Developing skills in performing
these procedures may be beneficial, especially in
countries where intravenous PAH therapy or lung
transplantation are not available. Continuous combi-
nation PAH-pharmacotherapy is required after atrial
septostomy or reverse Potts shunt for the underlying
advanced pulmonary vascular disease/PAH.
EXPERT RECOMMENDATIONS ON THE
DIAGNOSIS AND TREATMENT OF PH IN MLIRs
The majority of our recommendations (Table 7) are
extrapolated from previously published European or
North American guidelines and consensus statements
(5,6,11). Modification pertaining to MLIRs has mini-
mum data support and are predominantly expert
opinions (Level of Evidence: C). The focus is on
diagnosis and management of PH, keeping in mind a
high prevalence and a broad etiology of the disease.
Special attention is given to the diagnosis of LHD (i.e.,
rheumatic heart disease), acquired lung diseases (i.e.,
tuberculosis), infections such as HIV and schistoso-
miasis, and unrepaired CHD. The most significant
challenge in PH management includes unavailability
of PAH-targeted medication.
PERSPECTIVES FOR PH PATIENTS IN MLIRs
The perspectives for PH patients and their health care
specific to certain region and countries in MLIRs are
summarized in Table 6, and further discussed in
more detail in the Supplemental Appendix.
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SUMMARY AND GLOBAL PERSPECTIVES
PH is a progressive and often fatal condition that is
more common in MLIRs than in HIRs; PH is
underdiagnosed in MLIRs where it is handled by
cardiologists who often serve both children and
adults with limited access to advanced health care.
Importantly, on a global scale, PH is not a rare
disease but is a major health care burden world-
wide, for example, when associated with rheumatic
heart disease or CHD, SCD, thalassemia, HIV, or
schistosomiasis. Data from MLIRs regarding epide-
miology, etiology, management, and/or prognosis of
PH is still limited but is emerging from 6 patient
registries. Modifications to the international PH
guidelines, which are mostly based on studies from
HIRs, need to be made to address some of the
specific challenges faced in MLIRs. We propose a
pragmatic approach with clear cost-risk-benefit
evaluation along with an honest discussion among
health care providers, patients, and their families.
Registry and other collaborative study data for na-
tional advocacy and government supported health
care plans will be crucial for the managing of young
PH patients in MLIRs with limited economic
resources.
ADDRESS FOR CORRESPONDENCE: Dr. Babar S.
Hasan, Department of Pediatric and Child Health,
Stadium Road, P.O. Box 3500, The Aga Khan Univer-
sity Hospital, Karachi, Pakistan. E-mail: babar.
hasan@aku.edu. OR Dr. Georg Hansmann, Department
of Pediatric Cardiology and Critical Care, Hannover
Medical School, Carl-Neuberg-Str. 1, 30625 Hannover,
Germany. E-mail: georg.hansmann@gmail.com. Twitter:
@pvd_network.
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